Previous 10 | Next 10 |
While Precipio (PRPO) is a lesser-known company in the diagnostics and research industry, it generated significant market buzz in May 2021 when its COVID-19 antibody test became available on Amazon’s (AMZN) platform. However, can the stock continue to advance by relying on the antibody...
– Approval based on the phase 3 CheckMate -9ER pivotal trial, which showed CABOMETYX in combination with OPDIVO improved overall survival and doubled median progression-free survival and objective response rate versus sunitinib – Exelixis, Inc. (Nasdaq:...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology touches a broad swath of companies, spanning genomics and food production to biofuels and other niche industries. However, the vast majority of the time, the word “biotech” conjures up images of...
– Expanded collaboration to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development – Exelixis, Inc. (Nasdaq: EXEL) and Invenra, Inc. today announced that they have expand...
The following slide deck was published by Exelixis, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Exelixis, Inc. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Exelixis, inc (NASDAQ: EXEL) Q2 2021 Earnings Call Aug 5, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q2 2021 Earnings Conference Call August 5, 2021 05:00 PM ET Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer P.J. Haley...
Exelixis (NASDAQ:EXEL): Q2 Non-GAAP EPS of $0.37; GAAP EPS of $0.30 beats by $0.24. Revenue of $385.18M (+48.4% Y/Y) beats by $85.15M. Cash, cash equivalents, restricted cash equivalents and investments were $1.7 billion at June 30, 2021, compared to $1.5 billion at December 31, 2020. Raised ...
- Total Revenues of $385.2 Million, Cabozantinib Franchise Revenues of $284.2 Million - - GAAP Diluted EPS of $0.30, Non-GAAP Diluted EPS of $0.37 - - Raised Net Product Revenue Guidance to $1,050 - $1,150 Million and Total Revenue Guidance to $1,300 - $1,400...
The FDA has accepted Exelixis' (NASDAQ:EXEL) supplemental New Drug Application (sNDA) for CABOMETYX (cabozantinib) as a treatment for patients 12 years and older with differentiated thyroid cancer (DTC) who have progressed following prior therapy and are radioactive iodine-refractory. Th...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...